Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | NPC1 | O15118 | 1/20 | 0.33 |
| ▸ | TP53 | P04637 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | RAB9A | P51151 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | GRIN2B | Q13224 | 7/20 | 0.31 |
| ▸ | GRIN1 | Q05586 | 6/20 | 0.31 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.30 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.30 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.30 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22761958 | 0.76 | MEN1 (0.31) | MEN1NPC1RAB9AKMT2A | |
| SCHEMBL22419371 | 0.73 | PDE1A (0.38) | GRIN2BGRIN1KCNH2HRH4HRH3 | |
| SCHEMBL22761968 | 0.72 | GRIN2B (0.40) | SMN1; SMN2MEN1NPC1TP53MAPT | |
| SCHEMBL18123545 | 0.69 | KCNH2 (0.39) | SMN1; SMN2NPC1TP53RAB9AMAPK1 | |
| SCHEMBL12775630 | 0.68 | CYP17A1 (0.32) | GRIN2BGRIN1 | |
| SCHEMBL22152275 | 0.66 | PIK3CB (0.39) | SMN1; SMN2NPC1RAB9AGRIN2BGRIN1 | |
| SCHEMBL25606475 | 0.62 | PDE6A (0.38) | SMN1; SMN2NPC1TP53RAB9AKCNH2 | |
| SCHEMBL31347405 | 0.62 | ALDH1A1 (0.38) | SMN1; SMN2NPC1RAB9AKCNH2HRH4 | |
| SCHEMBL31347400 | 0.62 | ALDH1A1 (0.38) | SMN1; SMN2NPC1RAB9AKCNH2HRH4 | |
| SCHEMBL21530673 | 0.62 | GRIN1 (0.32) | GRIN2BGRIN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11466034-B2 | Compound functioning as bromodomain protein inhibitor, and composition | BETTA PHARMACEUTICALS CO., LTD. (CN) | 2022-10-11 | — | — | US | disclosed |
| US-20200385408-A1 | COMPOUND FUNCTIONING AS BROMODOMAIN PROTEIN INHIBITOR, AND COMPOSITION | BETTA PHARMACEUTICALS CO., LTD. (CN) | 2020-12-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11466034-B2 | Compound functioning as bromodomain protein inhibitor, and composition | BRD4, BRD1, BRD2 | SMN1; SMN2 3293/4885MEN1 1623/4885NPC1 2638/4885 |
| US-20200385408-A1 | COMPOUND FUNCTIONING AS BROMODOMAIN PROTEIN INHIBITOR, AND COMPOSITION | BRD4, BRD1, BRD2 | SMN1; SMN2 3293/4885MEN1 1623/4885NPC1 2638/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.